Yilmaz, Zeynep
Quattlebaum, Mary J.
Pawar, Pratiksha S.
Thornton, Laura M.
Bulik, Cynthia M.
Javaras, Kristin N.
Yao, Shuyang
Lichtenstein, Paul
Larsson, Henrik
Baker, Jessica H.
Funding for this research was provided by:
National Institute of Mental Health (T32MH076694, K01MH109782, R01MH120170, K01MH106675)
Brain and Behavior Research Foundation (NARSAD Young Investigator Award # 28799)
National Institute of General Medical Sciences (T32GM081740)
Vetenskapsrådet (538-2013-8864, 2004-1415)
Lundbeckfonden (R276-2018-4581)
National Institute of Diabetes and Digestive and Kidney Diseases (K23DK120517)
Forskningsrådet om Hälsa, Arbetsliv och Välfärd (2004-0383)
Article History
Received: 21 March 2022
Accepted: 1 November 2022
First Online: 9 December 2022
Declarations
:
: KNJ owns equity shares in Sanofi and Centene Corporation. CMB is a Scientific Advisory Board member for Shire, serves as a consultant for Idorsia (consultant), is an author with and royalty recipient from Pearson, and is on the Clinical Advisory Board of Equip Health Inc. HL reports receiving grants from Shire Pharmaceuticals, personal fees from and serving as a speaker for Medice, Shire/Takeda Pharmaceuticals and Evolan Pharma AB, and sponsorship for a conference on attention-deficit/hyperactivity disorder from Shire/Takeda Pharmaceuticals and Evolan Pharma AB. All other authors report no financial interests or potential conflicts of interest.
: The Swedish Twin study of CHild and Adolescent Development (TCHAD) was approved by the Ethics Committee of Karolinska Institutet, Stockholm, Sweden. This study was also approved by the Institutional Review Board of the University of North Carolina at Chapel Hill, where the data were analyzed.
: All parents and twins who participated provided informed consent.